Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2020 Financials and to Provide an Update on Development Programs on March 1, 2021
22 févr. 2021 06h45 HE
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will...
Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Offering
04 déc. 2020 12h54 HE
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its...
Reata Pharmaceuticals, Inc. Announces Pricing of Class A Common Stock Offering
01 déc. 2020 21h48 HE
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it has priced...
Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock
01 déc. 2020 16h03 HE
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the launch of a...
Reata Provides Update on Omaveloxolone Program for Patients with Friedreich’s Ataxia
24 nov. 2020 17h00 HE
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that the...
Reata Announces Positive Results From Year 2 of the Pivotal Phase 3 CARDINAL Study of Bardoxolone Methyl in Patients with Alport Syndrome
09 nov. 2020 06h45 HE
|
Reata Pharmaceuticals, Inc.
BARDOXOLONE ACHIEVED THE YEAR 2 PRIMARY AND KEY SECONDARY ENDPOINTS WITH STATISTICALLY SIGNIFICANT IMPROVEMENTS IN EGFR AS COMPARED TO PLACEBO AT WEEK 100 AND WEEK 104 BARDOXOLONE PATIENTS WHO...
Reata Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results and Provides an Update on Business Operations and Clinical Development Programs
09 nov. 2020 06h45 HE
|
Reata Pharmaceuticals, Inc.
REPORTED POSITIVE YEAR 2 DATA FROM THE PIVOTAL CARDINAL STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH CHRONIC KIDNEY DISEASE CAUSED BY ALPORT SYNDROME REPORTED LONG TERM EFFICACY DATA FROM EAGLE...
Reata Pharmaceuticals, Inc. to Report Third Quarter 2020 Financial Results and Provide an Update on Development Programs on November 9, 2020
02 nov. 2020 17h30 HE
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will...
Reata Announces Publication of Results From Pivotal Moxie Trial of Omaveloxolone in Patients with Friedreich’s Ataxia
26 oct. 2020 19h00 HE
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that results...
Reata Pharmaceuticals, Inc. Announces Presentation of KIDNEYCODE Program at the American Society of Nephrology Kidney Week 2020 Reimagined
15 oct. 2020 06h45 HE
|
Reata Pharmaceuticals, Inc.
PLANO, Texas, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (“Reata” or “the Company” or “we”) announced today the upcoming presentation of KIDNEYCODE: A Genetic Testing Program for...